Sign In
Buy VCEL
$34.74
+0.290 (+0.84%)
At Close: Jun 03, 2026
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
04:05pm, Thursday, 15'th Aug 2024
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in adv
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
08:30am, Wednesday, 07'th Aug 2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
What Makes Vericel (VCEL) a New Strong Buy Stock
01:01pm, Monday, 05'th Aug 2024
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Vericel Corporation (VCEL) Q2 2024 Earnings Call Transcript
03:58pm, Thursday, 01'st Aug 2024
Vericel Corporation (NASDAQ:VCEL ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Exe
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
10:06am, Thursday, 01'st Aug 2024
Vericel Corporation (VCEL) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
Vericel Reports Second Quarter 2024 Financial Results
07:55am, Thursday, 01'st Aug 2024
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profi
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
08:30am, Monday, 22'nd Jul 2024
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointm
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
08:30am, Thursday, 18'th Jul 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
The 3 Highest-Rated Medical Stocks You Can Buy Today
02:03pm, Thursday, 27'th Jun 2024
The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones.
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
08:30am, Tuesday, 11'th Jun 2024
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
08:30am, Wednesday, 22'nd May 2024
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col
Vericel Corporation (VCEL) Q1 2024 Earnings Call Transcript
02:36pm, Wednesday, 08'th May 2024
Vericel Corporation (NASDAQ:VCEL ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Execu
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
07:55am, Wednesday, 08'th May 2024
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance Raise
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
08:30am, Wednesday, 24'th Apr 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it wil
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
08:00am, Monday, 01'st Apr 2024
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
